According to the Director of VHIO, “the race in research against cancer has only just begun”
news
José Baselga and Josep Tabernero directly participate in the study, directed by William Hahn, of the Dana-Farber Cancer Institute of Boston
VHIO Scientific Manager is a pioneer in translational research
Queen Sofía and Councillor Marina Geli assist at the opening ceremony
This research studied the action mechanisms of two drugs—lapatinib and trastuzumab—in combination for the treatment of HER2-positive breast cancer. Lapatinib is a molecule which, when combined with trastuzumab, neutralizes the activity of the HER2 receptor and improves the effect of the antibody
